While a variety of human papillomavirus (HPV) tests and surrogate markers are available, currently there is no consensus on the best detection method(s) that should be used to identify HPV-related oropharyngeal squamous cell carcinomas and serve as a standard test (or tests) for routine diagnostic use. As we begin to consider using the results of HPV testing for clinical purposes beyond simple prognostication, such as making decisions on treatment dose or duration or for targeted therapies that may be highly dependent on viral-mediated pathways, we need to be more rigorous in assessing and ensuring the performance of the test (or tests) used. Here we provide an overview of the platforms and technologies, including the strengths and limitations of each test, and discuss what steps are needed to generate confidence in their performance for use in clinical practice.
Introduction
In addition to carcinomas of the uterine cervix, anus, vagina, vulva, and penis, squamous cell carcinoma of the oropharynx (OPSCC) is another tumor type that is recognized to be associated with human papillomavirus (HPV) infection [1] [2] [3] . The oropharynx, which is the midportion of the pharynx, includes the soft palate, the lateral and posterior walls of the pharynx, the palatine tonsils, and the base of the tongue (see Figure 1 ). Approximately 60-70% of newly diagnosed OPSCCs are associated with HPV in the United States and some parts of Europe [4] [5] [6] . It has been proposed that this preferential targeting of the oropharynx may reflect the biological interaction between HPV and the lymphoepithelium (i.e. reticulated epithelium) lining the tonsillar crypts, where strong expression of PD-L1 results in a diminished cytotoxic T-cell response to viral antigens and potentially creates an 'immune-privileged' site for viral infection and persistence [7, 8] .
It is also well acknowledged that patients with HPV-positive OPSCCs have better treatment responses and prognosis than patients with HPV-negative tumors [9] [10] [11] [12] [13] . Ragin et al performed a meta-analysis of retrospective studies and reported that patients with HPVpositive OPSCC had an estimated 50% reduction in risk of death when compared to patients with HPVnegative tumors [13] . A seeming exception is a variant form of oropharyngeal carcinoma with a high grade neuroendocrine phenotype (small cell carcinoma) which is indistinguishable from small cell carcinoma of the lung. These tumors seem to have aggressive clinical behavior regardless of HPV status [14, 15] .
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Head and Neck Cancers (NCCN Guidelines), Version 2.2017, state that the results of HPV testing should not change management decisions except in the context of a clinical trial. The NCCN Guidelines also state that, although HPV testing is not to be used to guide treatment, it is valuable in predicting oropharyngeal cancer prognosis, and tumor HPV testing is recommended as part of workup [16] . The NCCN Guidelines note that p16 protein expression is highly correlated with HPV status and recommend assessment of p16 expression by immunohistochemistry (IHC) as another test option besides detection of HPV DNA in tumor cell nuclei by in situ hybridization (ISH). Prognosis is so dependent on HPV status that a College of American Pathologists (CAP) expert panel also recently recommended routine HPV testing (via p16 IHC) for all patients with newly diagnosed OPSCC [17] . The American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) staging systems, which are based on equal grouping prognostication, were released in 2017 and now stage patients with oropharyngeal carcinoma differently by HPV status [18, 19] . The process of HPV-related head and neck cancer development. HPV is contracted and introduced to the oral cavity and oropharynx. The susceptibility of the reticulated tonsillar crypt epithelium leads to the development of persistent viral infection and carcinogenesis, with neoplastic transformation of squamous cells in the epithelium that then expand the surface and eventually invade into the surrounding stroma and lymphatics, metastasizing to LNs early in the disease course. The tumor cells are strongly and diffusely positive for p16 by IHC with both nuclear and cytoplasmic staining. The top figure depicts the anatomy of oropharynx, including soft palate, lateral and posterior walls of the oropharynx (side and back wall of the throat), palatine tonsil (tonsil), and base of tongue (back 1/3 of the tongue). The histological images represent normal oropharyngeal tonsillar crypt epithelium (×300, left), carcinoma in the tonsillar crypt (×200, second left), overtly invasive HPV+ OPSCC (×100, second right), and HPV + OPSCC p16 IHC staining (×200, right). (B) Illustration of molecular diagnostic tests based on the HPV genome, E6/E7 gene expression and overexpression of p16 protein. The HPV viral genome is presented that the viral DNA can be detected by PCR or ISH (left). When HPV virus in its transcriptionally active form, the E6 or E7 gene can be detected by RT-PCR or RNA ISH (top). HPV viral gene expression leads to abundant E7 protein overexpression with binding to Rb and mediating to its degradation. This allows for massive overexpression of p16 protein which is then detectable by IHC (right bottom). E: early genes; L: late genes; LCR: Long control region.
HPV testing is also critical in the workup of metastatic squamous cell carcinoma to cervical lymph nodes (LNs) of unknown primary. A positive HPV test result strongly suggests that an occult primary tumor is present in the palatine tonsil or base of tongue [20] . Selected HPV testing in these situations is recommended by the CAP guidelines, and the AJCC guidelines actually recommend staging such patients as T0 OPSCC. Treatment-wise, however, the NCCN Guidelines note that whether or not HPV positive status should be used to define radiation fields for occult primary tumors is still under investigation.
HPV detection technologies
Currently, the HPV tests that have been approved by the United States Food and Drug Administration (FDA) are those intended for use in cervical carcinoma. There are no HPV diagnostic tests with regulatory approval for oropharyngeal cancer. Rather, the HPV testing options available for use in the clinical setting for head and neck cancer are laboratory developed tests (LDTs), which can involve various techniques and platforms for the analysis of HPV DNA, HPV messenger RNA (mRNA), or the p16 protein. HPV E6 and E7 mRNA detection by reverse transcriptase polymerase chain reaction (RT-PCR) is highly correlated with improved patient survival in OPSCC and is considered by many to be the 'gold standard' test for classifying an OPSCC as being positive for transcriptionally active high-risk HPV [21, 22] . This involves reverse transcribing the mRNA into complementary DNA (cDNA) and then subsequently amplifying the target DNA sequences of interest using PCR. The other tests are judged for sensitivity and specificity in the literature mostly in comparison to RT-PCR mRNA detection from fresh frozen tissue. However, this requires technical expertise that is not routinely available in pathology laboratories and its interpretation is somewhat subjective based on amplification curve analysis. Use of fresh frozen tissues would be optimal. Recent advances have enabled the consistent and accurate measurement of E6/E7 mRNA in formalin-fixed paraffin-embedded (FFPE) tissue blocks going back 10-20 years or more, but this is not an established technique and is still technically challenging to perform reproducibly outside of the research laboratory setting [21] .
Another test that is widely used is the detection of HPV DNA using PCR. The most commonly used primer sets used to amplify specific HPV DNA sequences are PGMY09/11, GP5+/GP6+, and SPF10 LiPA, which all target consensus sequences of varying lengths (different primer sets target sequences of different lengths) within the HPV L1 gene [22] . These primer sets are designed to bind to a conserved region in multiple HPV types so that a large range of HPV types can be simultaneously identified. While PCR-based methods are known for high sensitivity in the detection of HPV, different PCR assays will vary in their performance based on the choice of primer sets, PCR protocols, and the type of tissue analyzed (e.g. fresh frozen versus FFPE) [22] . For example, because the fixation process often leads to DNA fragmentation, with strands that are shorter than 200bp, it is preferable to target short DNA sequences in FFPE samples to increase sensitivity [22] . HPV genotyping may then be performed separately, using restriction fragment length polymorphism (RFLP), linear probe assays, direct sequencing, or genotypespecific primers [23] , in order identify specific oncogenic HPV types for risk stratification.
One limitation of PCR assays is the possibility of obtaining false positive test results due to contamination of negative specimens from previously amplified specimens in the laboratory or from surrounding nonneoplastic tissue that is HPV infected [22] . Another is that there is no tissue context for the result (i.e. positivity cannot be identified directly in tumor cells in the tissue context). Perhaps the greatest limitation, though, is that PCR assays cannot distinguish 'clinically significant' HPV infections (i.e. HPV infections that results in transcriptional activity in tumor cells with expression of E6 and E7 genes) from those which are not [21] . Transcriptional activity is the key differentiator between clinically significant and insignificant HPV infection in tumors. This is the most established in OPSCC, where there are abundant data showing that only the tumors that harbor transcriptionally active high-risk HPV have significantly better survival [24] .
Still another test is HPV DNA detection by ISH. The ISH technique is based on labeled probes that hybridize to target HPV DNA sequences in the nuclei of tumor cells, and the probes can be either HPV-type specific or a cocktail to detect many different high-risk HPV types concurrently. The signals are visualized directly in the tumor, which provides tumor cell specific, direct histologic context to the result. This assay is known for its high specificity, but a weakness is limited sensitivity compared to other detection methods such as PCR, RT-PCR, and p16 immunostaining. False negative results are particularly likely when the viral load is low [25] . In addition, signal interpretation can be subjective due to lack of clean, clear staining signals. Studies have shown that up to 10% of cases have interobserver 215 Clinical HPV testing in OPSCC [26] . Most cases are clearly positive or negative, but pathologists must evaluate patchy, focal signals and decide if they represent true results or false positives due to nonspecific signal.
A relatively newer technique is RNA ISH, which is highly sensitive and highly specific because it can identify the presence of transcriptionally active HPV. One such test that has been used on OPSCC is the RNAscope Liquid-phase assays for cytopathology specimens are another type of assay that may be an option, particularly for evaluation of cervical LN metastases. These are the most commonly used tests for HPV screening in cervical cancer, with several commercially available HPV test kits approved by the FDA for the detection of high-risk HPV in cervical cytology: Hybrid Capture II (HC-2) (Qiagen, Gaithersburg, MD, USA); Cervista HPV HR assay and Cervista HPV16/18 assay (Hologic Inc., Bedford, MA, USA); Roche Cobas HPV test (Roche Molecular Systems, Pleasanton, CA, USA); and APTIMA HPV assay (Gen-Probe Inc., San Diego, CA, USA). The technical aspects of these assays are summarized in Table . These tests can also have technical and interpretation issues, however. For example, the primary issue with HC-2 analysis is the lack of an internal control to verify the presence of adequate tumor DNA in the sample, which may lead to false negative results [28] . Furthermore, the Roche Cobas test had lower specificity when compared to DNA ISH and p16 IHC [29] .
While investigators have begun exploring these tests for primary head and neck squamous cell carcinoma (HNSCC) specimens and for nodal metastases [28] [29] [30] , these tests are used sparingly in routine clinical practice for head and neck cancers and none of them are FDA approved for this purpose. Since a large fraction of HNSCC patients (and in particular OPSCC) are initially diagnosed based on cytology specimens from nodal metastases, these may be the only specimens available to establish a diagnosis. Thus, establishing an accurate and reliable method of HPV detection in cytologic samples is critical [31] . Table 2 summarizes the many of the studies conducted in recent years comparing commercially available tests for their performance in HNSCC specimens [28, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] .
The test that is most widely available in clinical laboratories and most widely used in clinical practice is p16 (INK4A) detection by IHC. This protein is a surrogate marker of transcriptionally active high-risk HPV infection. It functions as a tumor suppressor by binding to and inhibiting cyclin dependent kinase 4 and 6 (CDK4/6) so that it cannot phosphorylate the retinoblastoma protein (pRB). Hypophosphorylated pRB remains bound to E2F. Phosphorylation of pRB releases it from binding to E2F transcription factor to allow cell cycle progression [22] . Expression of p16 normally leads to the accumulation of hypophosphorylated pRB and thus to sequestration of E2F, with resulting G1 arrest [45] . In HPV-related carcinomas, viral E7 protein binds to pRB and leads to its degradation, which then allows E2F to bypass pRB-dependent cell cycle arrest [21, 46] . A secondary effect of pRB degradation is that E2F then stimulates the expression of p16, which accumulates in large amounts in the nuclei and cytoplasm of tumor cells (Figure 1) . p16 IHC is inexpensive, is performed on FFPE samples which are routinely generated in pathology laboratories as part of standard clinical surgical pathology practice, and has a sensitivity for transcriptionally active high-risk HPV that is almost 100% [47] . Different clones of p16 monoclonal antibodies are commercially available from different vendors. The most widely used is the E6H4 clone, originally linked with the CINtec p16 Histology kit (Roche, Heidelberg, Germany) which is specifically designed for evaluation of cervical dysplasia. This kit has CE-marking (i.e. the product can be legally placed on the market in the European Union), but the FDA approval for marketing in the United States is limited to intended uses in cervical cancer.
p16 IHC has demonstrated good agreement with HPV E6/E7 mRNA expression detected by RT-PCR [22] and RNA ISH. Extensive literature shows that p16 expression in OPSCC is associated with improved overall and disease specific survival independent of all other known prognostic factors with two to five times lower risk of adverse outcomes. A significant issue with p16 IHC is that, until recently, there has been no consensus on the definition of a positive p16 IHC result. It has been recognized for decades that there should be extensive overexpression of p16 for it to suitably be a surrogate of high-risk HPV, but how extensive has been debatable. Publications have varied and different laboratories have used different threshold levels (i.e. percentage of tumor cells that were stained) [22] . Cutoffs for the percentage of positive tumor cells needed have ranged from 1 to 5, 10, 50, 60, 70, or 75% of tumor cells [9, 20, 26, 27, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . Since very few tumors have borderline p16 expression (10-70% range), this has not been a formidable issue. However, newer guidelines are helping to clarify this, such as the CAP Guidelines recommending 70% nuclear and cytoplasmic expression of at least moderate or strong intensity for a definitive positive result. Borderline 219 Clinical HPV testing in OPSCC Hakima et al [35] 220 Kim et al nuclear and cytoplasmic p16 overexpression (50-70%) and diffuse, but weak, overexpression are uncommon but potentially significant problems. Since the small studies examining this issue have shown that most of these patients have transcriptionally active high-risk HPV in their tumors, the CAP guidelines suggest that patients with these borderline p16 results can undergo HPV specific testing to arbitrate whether or not to be classified as HPV-positive/HPV-related [17] . Another issue is that while p16 IHC is highly sensitive, its specificity for transcriptionally active HPV, even in the indicated clinical settings of oropharyngeal primary tumor and/or upper jugular nodal metastasis of unknown primary, can range from 79 to 95% because HNSCCs that are not HPV-related as well as benign squamous cells can overexpress p16 [31, 47, 49] . For example, almost one-half of benign squamous cells from branchial cleft cysts of the lateral neck overexpress p16 [59] , although it is rarely strong and diffuse. It should be kept in mind that the positive predictive value of any test depends highly on the disease prevalence. In the United States, where HPVpositivity amongst OPSCC patients is very high (70-90% in recent studies), the positive predictive value/correlation with HPV is higher. However, in areas where HPV-positive rates are lower, such as Han et al [36] *Most assays are tested and validated in cervical cancer. The assays are listed from the most commonly use pathological tests to the more technical challenged or advanced methodologies. Using the terminology and designs described by authors. †
The comparisons were made with p16 IHC using anti-p16 antibody (E6H4 clone from CINtec ® Histology, Roche mtm Lab, or from Ventana Medical Systems, Tucson, AZ, USA). The comparison with other assays is described specifically.
‡ CE marked for use for detection of HPV in cervical cancer in Europe. CE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA). CE Marking indicates a product's compliance with the applicable EU regulations and enables the commercialization of products in 32 European countries. § FDA approved for HPV detection for cervical cancer in USA.
221 Clinical HPV testing in OPSCC certain European populations (as low as 20%) and other geographic regions outside of the United States, the positive predictive value is lower, and p16 alone may not be the best approach for classifying patients [60] . Also, up to 26% of nonsquamous, basaloid carcinomas such as solid type adenoid cystic carcinoma, which are not associated with HPV, can be diffusely positive for p16 [61] . While some of these sinonasal carcinomas have been more recently shown to be the unique tumor 'HPV-related multiphenotypic carcinoma', the rest across other anatomic sites are not HPV-related [62, 63] . It has also been reported that p16 IHC is positive (using the high expression cutoff ) in as many as 20-30% of head and neck cutaneous and primary lung SCCs that are unrelated to HPV [64] . These findings, although they do not obviate it, underscore the need for caution with a p16 IHC only approach. In primary OPSCC patients and in the tightly defined locations and scenarios for patients with neck nodal metastatic SCC of unknown or uninvestigated primary site, p16 IHC alone is appropriate as recommended by the CAP, AJCC, and the World Health Organization [17] [18] [19] 65] .
Finally, investigators are in the early stages of development in testing new specimen types for HPV, such as saliva and plasma samples. For example, quantitative PCR-based HPV-16 DNA (E6 and E7 genes) in the saliva and plasma of OPSCC samples before and after treatment has been explored as a biomarker of recurrence [66] .
HPV assays in clinical trials
Standard therapies for OPSCC can involve high doses of toxic radiation and chemotherapy, which may be unnecessary for HPV-positive OPSCC, so clinicians are actively investigating whether reduced doses of radiation and chemotherapy (i.e. deintensification) may be appropriate for HPV-positive oropharyngeal cancers. There are substantial data supporting this idea in other HPV-related SCCs, such as cervical and anal SCC, as well as indirect data from head and neck cancer trials designed for other reasons. However, direct (and in particular prospective controlled clinical trial) data for OPSCC patients are limited. Recently, Chera et al published the results of their prospective clinical trial from which they concluded, 'for patients with favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, a substantially decreased intensity of therapy with 60 gray of intensity-modulated radiotherapy and weekly low-dose cisplatin produced better preservation of quality of life compared with standard therapies while maintaining excellent 3-year tumor control and survival' [67] . It should be noted that this was a small, single-arm phase II trial (1) without a control group receiving standard radiation and chemotherapy doses and (2) without a biomarker negative group. In these patients receiving reduced intensity chemoradiotherapy, the pathologic complete response rate was 86% and 3-year overall survival was 95%. The 44 patients enrolled in this trial were all p16-positive (>70% of carcinoma cells showing nuclear reactivity) but 36% were negative for HPV DNA (using fluorescence ISH), and it would have been interesting to see whether there was a difference in the outcome between the HPV+/p16+ and HPV −/p16+ groups. We should soon hear about the results from other ongoing clinical trials involving deintensification treatment protocols for HPV-associated locally advanced oropharyngeal cancer.
The National Clinical Trials Network (NCTN)/cooperative group clinical trials focused on HPV-positive OPSCC require documented p16 or HPV positivity as eligibility criteria. In the RTOG 1016 Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer (ClinicalTrials.gov Identifier: NCT01302834), the overall goal was to identify a less toxic approach for HPV-related OPSCC patients, in order to reduce the burden of acute toxicity and to facilitate quicker recovery of patients. For this trial, HPV-positive tumor status was determined by p16 expression, and all patients were required to submit their tissues for mandatory p16 analysis by a central laboratory. The reason for this mandatory testing was that p16 testing had not been standardized at a national level, resulting in up to 30% discordance between local and central testing. In this setting, tumor p16 expression was evaluated by means of IHC with a mouse monoclonal antibody (MTM Laboratories, Westborough, MA, USA) visualized with use of an autostainer (Discovery XT, Ventana, Tucson, AZ, USA) and a secondary detection kit (iVIEW DAB Detection Kit, Ventana) by standard protocol. Positive p16 expression was defined for these clinical trials as a strong and diffuse nuclear and cytoplasmic staining in 70% or more of the tumor cells. publication reporting on the trial's promising findings, which showed that radiotherapy deintensification may result in equivalent or similar response in selected patients compared to full-dose radiotherapy [68] , the investigators did not provide assay details other than citing the Jordan et al paper [49] . In the Jordan et al paper, p16 IHC was performed using the monoclonal antip16INK4a (MTM Laboratories, Heidelberg, Germany) and HPV16 DNA was detected in paraffin-embedded tumor samples using the GenPoint catalyzed ISH signal amplification system for biotinylated probes (Dako, Carpinteria, CA, USA). In this paper, the optimal cutpoint was determined to be the H score cutoff point of 60 indicating 'that a tumor with diffuse low-intensity nuclear and cytoplasmic p16 staining in the majority of the tumor is a true positive' and that 'the optimal cutoff point for percentage staining was lower at ≥35%' instead of the recommended cutoff point of ≥70% [49] . Because p16 IHC can lead to false positive results, the authors recommended 'For clinical trials evaluating 'deintensification' strategies for patients with HPV-associated OSCC, combined p16 IHC and HPV16 ISH is necessary to provide the high specificity required to avoid possible undertreatment of patients without a diagnosis of HPVassociated OSCC' [49] .
Need for harmonization of HPV tests
As described in previous sections, clinical HPV testing practices for OPSCC are variable, and there are many methods for HPV detection/patient prognostication, which vary in their platform, target, and performance with respect to sensitivity, specificity, and ability to stratify patient outcomes for positive versus negative results. While there are commonly used assays, there is no clear consensus among the pathologists and head and neck oncologists on which HPV test or tests should be required to reliably identify patients with transcriptionally active high-risk HPV-positive OPSCC. Although p16 IHC is easy to perform and every clinical histopathology lab should already have the capability to perform this test, we cannot take analytical validity for granted. As we move toward using HPV tests to help us make clinical treatment decisions regarding the type of therapy or intensity of treatment, we need to ensure the accuracy and reproducibility of the HPV test result through further studies.
In the newly published CAP guidelines for HPV testing in head and neck carcinomas in routine clinical practice, the recommendation for workup of patient specimens from oropharyngeal primary tumors is to perform p16 IHC testing, with lack of staining or <70% nuclear and cytoplasmic staining classified as HPV-negative and ≥70% nuclear and cytoplasmic staining classified as HPV-positive [17] . In addition, it is specified that the intensity should be moderate or strong. However, the CAP Guideline does not recommend one antibody, platform, or set of test conditions over another. The guideline is specifically focused on creating consistent, data-driven, HPV testing practices across practice settings. Admittedly, however, not having a standard test or tests (nor single platform for such tests or strong interassay concordance data) limits the ability to assure results for individual patients. And for p16 and HPV specific tests, needing a visual assessment of staining distribution and/or intensity brings risk for subjectivity into play.
In order to help support the needed harmonization studies, the National Cancer Institute (NCI) has active funding opportunity announcements (FOAs) for both cooperative grants and supplement grants. PAR-17-003 is the FOA for supplement grants to support projects that will clinically validate molecular assays and prepare for their use in clinical studies or trials for the treatment, prevention or control of cancer. Projects that improve standardization or harmonization of assay performance among laboratories are eligible for funding, and these types of project may involve continued efforts in assay optimization and ensuring concordance of assay results from different laboratories. Because these grants are meant to 'supplement' existing grants, the investigators need to be current recipients of an active R01 research project grant. PAR-18-317 and PAR-18-310 are FOAs for grants to support assay validation through the UH2 and UH3 cooperative agreement mechanisms. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are appropriate for these funding opportunities as well.
In conclusion, now that there is real clinical utility of HPV testing in the management OPSCC patients, more test validation and method comparison studies are needed to decide what specific tests to perform and in what settings, and to assess the concordance the tests between different clinical laboratories and establish procedures for harmonization. There is a great opportunity for standardizing practices.
